News for Prometheus Biosciences, Inc. (RXDX)

**media[465429]**

Merck & Co. lowered the top end of its full-year sales forecast after demand for its HPV vaccine fell for a second straight quarter in China.

Merck (MRK) has reduced its full-year sales guidance cap due to a second consecutive quarter of declining demand for its HPV vaccine in the Chinese market. In t

(Bloomberg) -- Merck & Co.’s shares fell the most in three years as light sales of its Gardasil HPV vaccine in China dimmed quarterly profit and sales that beat Wall Street estimates.Most Read from BloombergLuxury Heir Alleges His $13 Billion Hermès Fortune Has VanishedRich Hong Kong Families Sell Mansions at Discounts to Repay DebtVenezuela’s Opposition Says It Has Proof of Election FraudTesla Analyst Nearly Crashes While Using ‘Full Self-Driving’Harris’ Running-Mate Search Zeroes In on Three T

HanAll Biopharma Appoints Christopher W Slavinsky as Chief Business Development and Legal Officer

The dynamics of the inflammatory bowel disease market are anticipated to change in the coming years owing to the improvement in the diagnosis...

Biotech saw seven of the rounds on March's list. Those rounds alone totaled nearly $1.5 billion, making it quite the month for startups looking to develop drugs and therapies for all that ails us.

MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical…

Roivant Sciences Ltd., with its differentiated drug development pipeline and strategic investments, shows strong upside prospects in 2024. Click for my ROIV update.

Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines Fourth-Quarter Worldwide Sales Were $14.6 Billion, an Increase of 6% From Fourth Quarter 2022; Excluding...

SAN DIEGO, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a...

Sales Reflect Sustained Growth, Particularly in Oncology and Vaccines Total Worldwide Sales Were $16.0 Billion, an Increase of 7% From Third Quarter 2022; Excluding LAGEVRIO, Growth Was 6%;...

Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as patents for some of the industry's blockbuster drugs are on the expiration cliff.

Top healthcare stocks include Theravance Biopharma for best value, Dr Reddy's Laboratories for fastest growth, and Viking Therapeutics for most momentum.

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

Roivant Sciences recently won approval for a topical cream, VTAMA, that looks set to achieve blockbuster sales. Learn why I rate ROIV stock as a buy.

The team at City Index have looked at some of the largest ever IPOs and ranked them by total revenue to find out which were the biggest ones of all time.

In this piece, we will take a look at the twelve best stocks that have recently had their initial public offering.

Read Investment Analysts’ Upgrades for May 11th (ADDYY, AHT, ARCT, ARTNA, ARWR, ASHTY, AZEK, BNCDY, CELH, CLB) at ETF Daily News